Cagent Vascular Advances Serration Remodeling Therapy Profile With New Clinical Focus and Symposium Spotlight

Cagent Vascular Inc featured prominently this week as it continued to spotlight its Serration Remodeling Therapy, or SRT, for peripheral artery disease and chronic limb-threatening ischemia. Multiple LinkedIn posts and a high-profile presentation at the Charing Cross Symposium 2026 underscored the technology’s potential to address elastic recoil and improve long-term vessel patency.

At Charing Cross, Dr. Frank Arko discussed the challenge of elastic recoil in peripheral arterial disease and positioned SRT as a candidate for a new standard of care. The therapy uses low-pressure, controlled serration to modify the arterial wall, aiming to achieve more predictable and durable outcomes than standard balloon angioplasty.

Cagent Vascular also highlighted SRT’s application in chronic limb-threatening ischemia, particularly in complex pedal interventions for limb preservation. The company emphasized the importance of safe, controlled luminal gain to support wound healing and long-term limb salvage in this underserved segment.

Clinical data from the PRELUDE-BTK study were showcased, with imaging demonstrating controlled, linear micro-fissures, a reported 21.8% residual stenosis, and a 1.9% bailout stent rate. The study cited 97.7% freedom from clinically driven target lesion revascularization at six months, reinforcing SRT’s potential durability profile in below-the-knee interventions.

Across its communications, Cagent Vascular framed SRT as offering both clinical and economic advantages by potentially reducing restenosis and repeat procedures. Growing visibility at international forums and continued collaboration with key opinion leaders may support broader physician awareness, clinical adoption, and, over time, improved revenue prospects for the platform.

While the company did not disclose new financial metrics or regulatory milestones, the week’s updates collectively signal a strategic push to entrench SRT in peripheral vascular care. If ongoing clinical work and data generation sustain positive results, Cagent Vascular could further strengthen its niche position in the endovascular devices market.